The federal government is clawing back $11.4 billion in COVID-19 funding, a move that could affect local and state public health efforts across the US.

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

Barriers to wider use of AI in oncology include inaccuracy, workflow challenges, environmental impacts, and more.

Americans living in rural communities could see their access to health care diminish if Congress changes eligibility for Medicaid or significantly reduces funding.

(HealthDay News) — Grants from the National Institutes of Health (NIH) that were funding research on LGBTQ+ health have been canceled by the US government, alarming scientists who say the move will ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) for use in patients with prostate cancer.